Under one in 10 individuals who could benefit from obesity jabs such as Wegovy are able to get them, warns the WHO as it issues its inaugural guidance on the medications.
Given more than one billion individuals worldwide now classified as obese, it is advocating for increased and just access to this class of drugs.
Per forecasts, more than two billion could be obese by 2030 without intervention.
"The new guidelines affirms that obesity is a lifelong illness that can be addressed with comprehensive and ongoing care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are key barriers to universal availability to the jabs that can aid individuals in losing substantial weight, notes the body.
Weight-Loss Drug Supply Crisis
Despite the present most favorable case, the manufacturing of these medications might only reach approximately 100 million people – fewer than 10% of those who need them, according to the health organization.
The advice calls on governments and firms to increase availability, through strategies including voluntary licensing.
Exclusive production rights on semaglutide – the primary ingredient of a leading brand – is due to expire in a number of nations in 2026.
How Obesity Jabs Operate
The injections imitate a biological compound to slow digestion, curb appetite and enhance the sense of being full so users reduce food intake.
Individuals usually start to lose weight after several weeks of beginning the once-weekly jabs.
Research indicates patients may regain a significant portion within a year of discontinuing the medication, because their normal food cravings return.
To be above a healthy weight increases your risk for experiencing medical conditions, like type 2 diabetes, heart disease, brain attack, and specific cancers.
Excess weight affects people in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, as per the WHO.
